HOME > TOP STORIES
TOP STORIES
-
BUSINESS Kyowa Kirin Picks Abdul Mullick as New President and COO
November 1, 2024
-
BUSINESS Otsuka Holdings Names Makoto Inoue as New CEO
November 1, 2024
-
REGULATORY BeiGene’s Brukinsa, J&J’s Balversa and More Now in Line for Japan Approval
October 31, 2024
-
BUSINESS 604 Employees Raise Hands for Sumitomo’s Buyout Program
October 31, 2024
-
ACADEMIA 50% of Quit-Smoking Clinics Closed or Suspended, Will Champix Re-Supply Bring Them Back Online?
October 30, 2024
-
REGULATORY Ruling Bloc’s Loss of Lower House Majority Might Sway Off-Year Revision Debates
October 29, 2024
-
REGULATORY LDP Loses Big in Snap Election, Many Health-Savvy Members Ousted
October 28, 2024
-
BUSINESS AbbVie Taps Tiago Campos Rodrigues as Japan President
October 28, 2024
-
BUSINESS Recordati to Enter Japan’s Hematology/Oncology Market with Enjaymo Acquisition
October 25, 2024
-
BUSINESS NHI-Market Price Gap Expected to Contract in 2024, Will It Enter Lower 5% Territory?
October 24, 2024
-
BUSINESS CEA Is “Wrong Tool” That Doesn’t Fit into Japanese System: J&J Exec
October 23, 2024
-
REGULATORY LDP’s Hashimoto Makes Rare Speech on Drug Prices amid Close Race in Okayama
October 22, 2024
-
BUSINESS Pfizer Veteran Pullicino to Lead Novartis Japan
October 22, 2024
-
BUSINESS Ferring Japan Set for 15% Annual Growth as It Gazes at Gene Therapy Debut
October 21, 2024
-
BUSINESS Moderna CEO Maintains Future Vision for Product Mix despite R&D Cutback, Eyes Leap with Flu-COVID Shot
October 18, 2024
-
BUSINESS Ultragenyx Looks to Launch 6 New Products in Japan by 2028-End: CCO
October 17, 2024
-
REGULATORY Multiple Candidates Tout Drug Policies as Snap Poll Campaigning Starts
October 16, 2024
-
BUSINESS Shonan iPark Set for Expansion as It Looks to Establish Profile as Regenerative Medicine Hub
October 16, 2024
-
REGULATORY Japan Political Parties Push Varied Pharma Policies as Election Campaign Kicks Off
October 15, 2024
-
ORGANIZATION EFPIA Chief Sees Positive Signal from Japan Policymakers, Calls for Consistency
October 11, 2024
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
